Monthly Prescribing Reference

Xhance Approved for Chronic Rhinosinusitis Without Nasal Polyps

Findings showed treatment with Xhance was associated with a statistically significant improvement on both study endpoints compared with placebo. The Food and Drug Administration (FDA) has approved ...
Nasdaq

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays

Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose ...
Nasdaq

Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ...
Healthline

Xhance Interactions: Alcohol, Medications, and Others

Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other medications, ...
MedPage Today

First Treatment Approved for Chronic Rhinosinusitis Without Nasal Polyps

The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...